Imbruvica

Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease and currently being evaluated in multiple types of cancer and for other serious diseases.

Type of Molecule

Small Molecule

Target

BTK

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Chronic Graft versus Host Disease (cGVHD) US, EU
Approved
Diffuse Large B-cell Lymphoma (DLBCL) US, EU
Phase 3
Follicular Lymphoma (FL) US, EU
Phase 3
Relapsed/Refractory Marginal Zone Lymphoma (MZL) US, EU
Approved
Pancreatic Cancer US, EU
Phase 3
Solid Tumors US, EU
Phase 2